CellResearch Corporation was founded in Singapore in 2002 by scientists with a keen interest and expertise in Cell Biology. It’s original remit was to provide skin and scar cells to laboratories around the world for research, as well as to perform contract research for cell laboratories internationally. 

In 2004, our scientists isolated Epithelial and Mesenchymal Stem Cells from the Umbilical Cord Lining Membrane. This novel and significant discovery was put up for intellectual property protection, and to date we have patents granted in multiple strategic key territories around the world.

The umbilical cord lining membrane is now known to be the richest source of stem cells in the body, and both epithelial and mesenchymal stem cells are being researched intensively with collaborators all around the world to exploit their potential for downstream medical therapy. Considerable headway has already been achieved, and we are due shortly to start USFDA Clinical Trials with our collaborators in the USA, leading to a therapy to accelerate wound healing.

To maximise future Cord Lining Stem Cell use, CellResearch Corporation feels that the membrane from which the cells are derived should be stored. Today we license our proprietary technology to partners who bank Cord Lining Membrane in various territories around the world. 

Our extensive experience with Cord Lining Stem Cells has taught us much, and we have been able to utilise this knowledge to produce a ground breaking cosmeceutical line called CALECIM® which has been observed to improve the skin appearance after topical application.

A group of companies has since been established in order to manage the various businesses related to Cord Lining Stem Cells:

CordLabs Pte Ltd and CordLabs Asia Pte Ltd support the umbilical cord tissue banking industry, which allows parents to bank the cord lining of their baby’s umbilical cord.

CordLabs owns and manages the Global Cord Registry (GCR) where banked cord lining tissues are registered after careful analysis and confirmation that the banked tissues are processed by the licensed banking provider using our proprietary protocols and with the requisite care to allow the outgrowth of Cord Lining Stem Cells. The GCR functions as a guarantee for both the physician and the patient that registered cord tissue samples are harvested and stored using our proprietary technology. The cells contained will be available to be harvested for therapy.

CALECIM Cosmeceuticals Pte Ltd is a skin care company based on CALECIM®.

CellResearch Intellectual Properties Pte Ltd was set up to manage the patents and legal matters of the group.